BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $401.00.

Several research firms recently issued reports on ONC. Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target for the company in a research report on Monday, January 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $405.00 price objective on shares of BeOne Medicines in a report on Thursday, January 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $420.00 price objective on shares of BeOne Medicines in a research note on Monday, November 17th. Guggenheim increased their target price on BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Truist Financial raised their target price on BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, February 27th.

Insiders Place Their Bets

In other BeOne Medicines news, CEO John Oyler sold 75,631 shares of BeOne Medicines stock in a transaction on Monday, December 15th. The stock was sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the completion of the transaction, the chief executive officer directly owned 24,369 shares of the company’s stock, valued at approximately $7,500,534.51. This trade represents a 75.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 102,665 shares of company stock valued at $31,561,896. Company insiders own 6.62% of the company’s stock.

Institutional Trading of BeOne Medicines

Several large investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC acquired a new stake in shares of BeOne Medicines during the second quarter worth approximately $373,000. KBC Group NV acquired a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $2,175,000. PNC Financial Services Group Inc. bought a new stake in BeOne Medicines during the 2nd quarter worth approximately $228,000. Geode Capital Management LLC bought a new stake in BeOne Medicines during the 2nd quarter worth approximately $8,622,000. Finally, Fiera Capital Corp acquired a new stake in BeOne Medicines during the 2nd quarter valued at $5,062,000. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Stock Down 0.4%

ONC opened at $284.05 on Friday. The company has a market capitalization of $31.15 billion, a P/E ratio of 112.72 and a beta of 0.53. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.41 and a quick ratio of 3.08. The firm’s fifty day moving average price is $334.52 and its two-hundred day moving average price is $329.69. BeOne Medicines has a fifty-two week low of $196.45 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. On average, analysts anticipate that BeOne Medicines will post -5.82 EPS for the current year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.